Masashi Fujino

National Cerebral and Cardiovascular Center
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

BACKGROUND: Calcified nodules (CNs) represent a high-risk coronary lesion phenotype associated with target lesion revascularization (TLR). Although rotational atherectomy (RA) is an established treatment for calcified lesions, its benefit for CNs remains unclear. This study aimed to evaluate the impact of RA on TLR and to identify specific morphological features on intravascular ultrasound that may influence its therapeutic effect for CNs. METHODS: In a substudy of the U-SCAN registry (Coronary Intravascular Ultrasound for Calcified Nodule), 348 patients with CNs identified by intravascular ultrasound who underwent percutaneous coronary intervention were analyzed. We excluded patients with in-stent restenosis, use of alternative debulking devices, failed device passage without RA, and poor image quality. The final analysis included 209 patients, stratified by RA use. Multivariable Cox proportional hazards models were used to identify predictors of TLR and assess treatment interactions across subgroups. RESULTS: Among 209 patients, 79 patients (37.8%) underwent RA. During a median follow-up of 2.1 years (interquartile range, 0.4–4.9), TLR was required in 20 of 79 patients (25.3%) in the RA group and 41 of 130 patients (31.5%) in the non-RA group. After adjustment, RA independently predicted reduced TLR (hazard ratio, 0.34 [95% CI, 0.19–0.62], P <0.001). In addition, intravascular ultrasound–derived calcification features, including greater lumen area stenosis, longer CN length, smaller final minimum lumen area, and adjacent circumferential calcification, were significantly associated with TLR. Notably, the benefit of RA on TLR was pronounced in patients with contralateral calcification (8.6% versus 51.6%, P <0.001). In contrast, without this feature, the TLR rate was higher in the RA group (38.6% versus 25.3%, P =0.11), resulting in a statistically significant interaction ( P interaction <0.001). CONCLUSIONS: In patients with CNs, RA was associated with a reduced long-term risk of TLR. The presence of contralateral calcification identifies a subgroup deriving substantial benefit, supporting a more selective, morphology-guided approach to treatment. REGISTRATION: URL: https://jrct.mhlw.go.jp/ ; Unique identifier: jRCT1050240037.

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Obesity has become a pandemic in the Asia-Pacific region, with an alarming rate of increase in the prevalence of obesity. The impact of obesity and its associated comorbidities goes beyond the healthcare system, posing a substantial burden not only on the individual, but also on the society and the economy. In this review, we focus on the latest situation in the Asia-Pacific region, and review the diagnostic criteria of obesity, management strategies and access to treatment in the region. National guidelines on obesity management are available in some countries, reflecting the recognition of the problem of obesity by healthcare professionals and government bodies. Although a range of anti-obesity pharmacotherapies and bariatric surgeries are available, access remains restricted and reimbursement criteria vary in different parts of the Asia-Pacific. Prevention is key, as treatment alone cannot reverse the tide of obesity, and a sustained partnership between the patient and the clinician is necessary to manage the chronic disease of obesity.

Year:

2024

BACKGROUND: Cardiovascular events still occur at intermediate stenosis with fractional flow reserve (FFR) ≥0.81, underscoring the additional measure to evaluate this residual risk. A reduction in distal coronary artery pressure/aortic pressure (Pd/Pa) from baseline to hyperemia (ie, change in Pd/Pa) reflects lipidic burden within vessel walls. We hypothesized that this physiological measure might stratify the risk of future cardiac events at deferrable lesions. METHODS: Lesion- (899 intermediate lesions) and patient-based (899 deferred patients) analyses in those with FFR ≥0.81 were conducted to investigate the association between change in Pd/Pa and target lesion failure (TLF) and major adverse cardiac events at 7 years, respectively. RESULTS: The occurrence of TLF and major adverse cardiac events was 6.7% and 13.4%, respectively. The incidence of target lesion–related nonfatal myocardial infarction was 0.6%. Lesions with TLF had a greater change in Pd/Pa (0.11±0.03 versus 0.09±0.04; P =0.002), larger diameter stenosis (51.0±9.2% versus 46.4±12.4%; P =0.048), and smaller FFR (0.84 [0.82–0.87] versus 0.86 [0.83–0.90]; P =0.02). Change in Pd/Pa (per 0.01 increase) predicted TLF (odds ratio, 1.16 [95% CI, 1.05–1.28]; P =0.002) and major adverse cardiac event (odds ratio, 1.08 [95% CI, 1.01–1.16]; P =0.03). Lesions with change in Pd/Pa ≥0.10 had 2.94- and 1.85-fold greater likelihood of TLF (95% CI, 1.30–6.69; P =0.01) and major adverse cardiac event (95% CI, 1.08–3.17; P =0.03), respectively. Lesions with FFR ≤0.85 had a substantially higher likelihood of TLF when there is a change in Pd/Pa ≥0.10 (12.4% versus 2.9%; hazard ratio, 3.60 [95% CI, 1.01–12.80]; P =0.04). However, change in Pd/Pa did not affect TLF risk in lesions with FFR ≥0.86 (3.8% versus 3.7%; hazard ratio, 0.56 [95% CI, 0.06–5.62]; P =0.62). CONCLUSIONS: Despite deferrable FFR values, lesions and patients with a change in Pd/Pa ≥0.10 had higher cardiovascular risk. Change in Pd/Pa might help stratify lesion- and patient-level risks of future cardiac events in those with FFR ≥0.81.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Koshiro Kanaoka

Nara Medical University

JAPAN
View details

Satoshi Honda

National Cerebral and Cardiovascular Center

JAPAN
View details

Adam Nelson

Associate Professor

University of Adelaide

AUSTRALIA
View details

Kota Murai

Medical Doctor

National Cerebral and Cardiovascular Center

JAPAN
View details